Landmark ECOG-ACRIN ENDURANCE Study Co-Authored by International Myeloma Foundation Leaders Provides Evidence for Optimal Duration of Maintenance Therapy

Phase III ENDURANCE (E1A11) trial results were published in the New England Journal of Medicine. The study is randomized, prospective, and was designed and conducted by the ECOG-ACRIN Cancer Research Group, but the article text provides no efficacy/safety numbers or implications for outcomes.

Analysis

Phase III ENDURANCE (E1A11) trial results were published in the New England Journal of Medicine. The study is randomized, prospective, and was designed and conducted by the ECOG-ACRIN Cancer Research Group, but the article text provides no efficacy/safety numbers or implications for outcomes.